Bibliography

1. Karch CM, Goate AM. Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis. *Biological Psychiatry.* 2015;77(1):43-51.

2. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *The Lancet Neurology.* 2013;12(2):207-216.

3. Weekman EM, Sudduth TL, Caverly CN, et al. Reduced Efficacy of Anti-Abeta Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity. *J Neurosci.* 2016;36(38):9896-9907.

4. Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. *The Lancet Neurology.* 2016;15(9):934-943.

5. Liu E, Schmidt ME, Margolin R, et al. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. *Neurology.* 2015;85(8):692-700.

6. Dumitrescu L, Mayeda ER, Sharman K, Moore AM, Hohman TJ. Sex difference in the genetic architecture of Alzheimer’s disease. *Current Genetic Medicine Reports.* 2019.

7. 2018 Alzheimer's disease facts and figures. *Alzheimer's & Dementia.* 2018;14(3):367-429.

8. Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DAJAN. Sex differences in Alzheimer’s disease and common neuropathologies of aging. 2018.

9. Carroll JC, Rosario ER, Kreimer S, et al. Sex differences in beta-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. *Brain Res.* 2010;1366:233-245.

10. Yue M, Hanna A, Wilson J, Roder H, Janus C. Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. *Neurobiol Aging.* 2011;32(4):590-603.

11. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. *Archives of General Psychiatry.* 2005;62(6):685-691.

12. Koran MI, Wagener MA, Hohman TJ. Sex Differences in the Association between AD Biomarkers and Cognitive Decline. *Brain Imaging and Behavior.* 2017;11(1):205-213.

13. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. *APOE* and Alzheimer Disease Meta Analysis Consortium. *JAMA.* 1997;278.

14. Neu SC, Pa J, Kukull W, et al. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. *JAMA neurology.* 2017.

15. Hohman TJ, Dumitrescu L, Barnes LL, et al. Sex-specific effects of Apolipoprotein E with cerebrospinal fluid levels of tau. *JAMA Neurology.* 2018.

16. Deming Y, Dumitrescu L, Barnes LL, et al. Sex-specific genetic predictors of Alzheimer’s disease biomarkers. *Acta neuropathologica.* 2018:1-16.

17. Deming Y, Li Z, Kapoor M, et al. Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. *Acta Neuropathologica.* 2017;133(5):839-856.

18. Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in Alzheimer disease—the gateway to precision medicine. 2018:1.

19. Stern Y. *Cognitive reserve: Theory and applications.* Psychology Press; 2013.

20. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease. *Clarifying terminology for preclinical studies.* 2018;90(15):695-703.

21. Hohman TJ, Bush WS, Lan J, et al. Discovery of gene-gene interactions across multiple independent datasets of Late Onset Alzheimer Disease from the Alzheimer’s Disease Genetics Consortium. *Neurobiology of Aging.* 2016;38:141-150.

22. Hohman TJ, Chibnik L, Bush WS, et al. GSK3β Interactions with Amyloid Genes: An Autopsy Verification and Extension. *Neurotoxicity Research.* 2015;28(3):232-238.

23. Hohman TJ, Dumitrescu L, Cox NJ, Jefferson AL. Genetic resilience to amyloid related cognitive decline. *Brain Imaging and Behavior.* 2016:1-9.

24. Hohman TJ, Koran ME, Thornton-Wells TA. Interactions between GSK3B and amyloid genes explain variance in amyloid burden. *Neurobiology of Aging.* 2014;35(3):460-465.

25. Hohman TJ, Koran MEI, Thornton-Wells TA, Initiative AsN. Genetic variation modifies risk for neurodegeneration based on biomarker status. *Frontiers in Aging Neuroscience.* 2014;6.

26. Hohman TJ, Koran MI, Thornton-Wells TA. Genetic Modification of the Relationship between Phosphorylated Tau and Neurodegeneration. *Alzheimer's & Dementia.* 2014;10(6):637-645.

27. Hohman TJ, McLaren DG, Mormino EC, et al. Asymptomatic Alzheimer disease Defining resilience. *Neurology.* 2016;87(23):2443-2450.

28. Varma VR, Varma S, An Y, et al. Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. *Mol Psychiatry.* 2017;22(1):13-23.

29. Lane EM, Hohman TJ, Jefferson AL. Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers. *Brain Imaging Behav.* 2017;11(6):1779-1786.

30. Gamazon ER, Wheeler HE, Shah KP, et al. A gene-based association method for mapping traits using reference transcriptome data. *Nature Genetics.* 2015;47(9):1091-1098.

31. Caioli S, Severini C, Ciotti T, et al. Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer's disease. *Neuropharmacology.* 2017;116:82-97.

32. Mateo I, Llorca J, Infante J, et al. Low serum VEGF levels are associated with Alzheimer's disease. *Acta Neurologica Scandinavica.* 2007;116(1):56-58.

33. Leung YY, Toledo JB, Nefedov A, et al. Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. *Alzheimer's & dementia (Amsterdam, Netherlands).* 2015;1(3):339-348.

34. Neuner SM, Wilmott LA, Hoffmann BR, Mozhui K, Kaczorowski CC. Hippocampal proteomics defines pathways associated with memory decline and resilience in ‘normal’aging and Alzheimer’s disease mouse models. *Behavioural Brain Research.* 2017;322:288-298.

35. Neuner SM, Hohman TJ, Richholt R, et al. Systems genetics identifies modifiers of Alzheimer's disease risk and resilience. *bioRxiv.* 2017:225714.

36. Neuner SM, Garfinkel BP, Wilmott LA, et al. Systems genetics identifies Hp1bp3 as a novel modulator of cognitive aging. *Neurobiology of Aging.* 2016;46:58-67.

37. Yan D, Hu B, Darst BF, et al. Biobank-wide association scan identifies risk factors for late-onset Alzheimer's disease and endophenotypes. 2018:468306.